724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata

斑秃 医学 脱发 安慰剂 特应性皮炎 内科学 皮肤病科 银屑病 胃肠病学 免疫学 病理 替代医学
作者
David Rosmarin,Neil S. Sadick,Timothy Rodgers,Edward Lain,Lawrence Osman,Stephen M. Schleicher,Adam Reich,Jacek C Szepietowski,Agnieszka Owczarczyk‐Saczonek,Wojciech Baran,Bartłomiej Kwiek,Michal Torz,Jacek Zdybski,Sohail S. Chaudhry,Zachary Lee,Heng Xu,Yi Liu,Brian Lewis,Katie Mellskog,Lucinda M Elko-Simms
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:191 (Supplement_2)
标识
DOI:10.1093/bjd/ljae266.097
摘要

Abstract Introduction & Objectives Alopecia areata (AA) is a chronic inflammatory skin disorder resulting in patchy, non-scaring hair loss. The pathogenesis for AA involves loss of immune privilege for the hair follicle through overactivity of the Th1 and Th17 cells and dysfunction of regulatory T cells (Treg).1 Rezpegaldesleukin (REZPEG: NKTR-358) is a polyethylene glycol (PEG)-conjugated recombinant human interleukin 2 (rhIL-2) with the ability to selectively promote the activation and up-to 12-fold expansion of Tregs, while having relatively minimal effect on conventional T cells (Tcons).2 REZPEG is a biologic therapy and represents a potential novel therapeutic approach for patients with severe to very-severe AA. There are currently no biologic therapies approved for the treatment of AA. REZPEG has previously demonstrated clinical activity in patients with chronic inflammatory skin conditions, including atopic dermatitis (AD), psoriasis, and systemic lupus erythematous. Specifically, a Phase 1b study of REZPEG for patients with moderate-to-severe AD demonstrated a rapid time to response (2-4 weeks) during induction therapy and a prolonged durability of response, i.e., throughout the 36-week follow-up after cessation of therapy. These results support further development of REZPEG for patients with moderate to severe AD (phase 2b study ongoing, NCT06136741) and other inflammatory skin diseases, including AA. Objective Evaluate the efficacy and safety of REZPEG in patients with severe alopecia areata. Materials & Methods We are conducting a Phase 2b, randomized, double-blinded, placebo-controlled, international, multicenter study of REZPEG vs placebo for JAK-inhibitor naïve patients with severe to very severe AA. Eligibility requires adult males (aged 18-60 years) or adult females (aged 18-70) with severe to very severe AA with the following inclusion criteria: baseline Severity Alopecia Tool (SALT) score ≥ 50, stable hair loss for 6-months, current episode of severe AA of less than 8-years, and no hair loss from causes other than AA. Patients will be randomly assigned in a 3:3:2 ratio to 2 different REZPEG dosing regimens vs. placebo, administered subcutaneously, during the treatment period and all patients will undergo an extended follow-up. The primary endpoint for this study is the percent change from baseline in SALT score at end of treatment period. Key secondary/exploratory endpoints include the following: percent change from baseline in SALT score at other assessed timepoints, proportions with ≥ 50%, 75%, 90% reduction in SALT at end of treatment period and other assessed timepoints, proportion of patients with absolute SALT score ≤ 10, ≤ 20, ≤ 30, ≤ 50 at end of treatment period and other assessed timepoints, safety/tolerability, various patient reported outcomes (PROs), pharmacokinetics, and pharmacodynamics. Results Trial ongoing (NCT 06340360). Conclusion REZPEG is a novel regulatory T cell stimulating therapy that may confer prolonged therapeutic benefit for patients with chronic inflammatory skin conditions, including AA and AD. This phase 2b trial is evaluating the efficacy and safety of multiple dosing regimens of REZPEG in JAK-inhibitor and biologic-therapy naïve patients with severe to very severe alopecia areata.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
嘤嘤怪完成签到,获得积分10
1秒前
共享精神的应助被李密采纳,获得10
1秒前
2秒前
水煮电吹风的应助被洋洋洋采纳,获得10
2秒前
wsw111完成签到,获得积分10
2秒前
3秒前
chen完成签到,获得积分10
3秒前
4秒前
xiaoyi发布了新的文献求助10
5秒前
zhaohu47完成签到,获得积分10
5秒前
cdercder的应助被伊莎贝拉采纳,获得10
5秒前
wsw111发布了新的文献求助10
6秒前
6秒前
6秒前
一只咸鱼罢了完成签到,获得积分10
7秒前
打打的应助被LgY采纳,获得10
7秒前
务实成龙完成签到,获得积分10
7秒前
7秒前
将将完成签到,获得积分10
7秒前
8秒前
上官若男的应助被qingxuan采纳,获得10
8秒前
8秒前
luo完成签到,获得积分20
8秒前
搞怪的乐荷完成签到,获得积分10
10秒前
書生途发布了新的文献求助10
11秒前
11秒前
11秒前
wangxiangqin发布了新的文献求助10
12秒前
luo发布了新的文献求助10
12秒前
ws完成签到,获得积分10
12秒前
FossilGitter8完成签到,获得积分10
12秒前
灵巧谷波完成签到,获得积分10
13秒前
信仰完成签到,获得积分10
13秒前
英俊的铭的应助被冉123采纳,获得10
15秒前
15秒前
科研通AI65的应助被白糖采纳,获得10
15秒前
xiaoxun369完成签到 ,获得积分20
17秒前
小马甲的应助被榴莲采纳,获得30
17秒前
无限夏之完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640